AN OVERVIEW OF CURRENT RESULTS WITH THE VINCRISTINE-IRINOTECAN-TEMOZOLOMIDE COMBINATION WITH OR WITHOUT BEVACIZUMAB IN PEDIATRIC, ADOLESCENCE AND ADULT SOLID TUMORS.

[1]  G. Papageorgiou,et al.  Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab. , 2020, Anti-cancer drugs.

[2]  C. Weldon,et al.  The use of interval‐compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor , 2020, Pediatric blood & cancer.

[3]  U. Dirksen,et al.  Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). , 2020, Journal of Clinical Oncology.

[4]  James R. Anderson,et al.  Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Park,et al.  Vincristine, irinotecan, and temozolomide as a salvage regimen for relapsed or refractory sarcoma in children and young adults. , 2019, Journal of Clinical Oncology.

[6]  K. McHugh,et al.  Randomized phase 2 trial of the combination of vincristine and irinotecan with or without temozolomide, in children and adults with refractory or relapsed rhabdomyosarcoma (RMS). , 2019, Journal of Clinical Oncology.

[7]  H. Lederman,et al.  Irinotecan and vincristine for the treatment of refractory desmoplastic small round cell tumor in a developing country: a case report , 2019, Journal of Medical Case Reports.

[8]  R. Kebudi,et al.  Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience , 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[9]  S. Ferrari,et al.  Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients , 2018, Acta oncologica.

[10]  R. Bagatell,et al.  VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma , 2018, Pediatric blood & cancer.

[11]  H. Moritake,et al.  Successful treatment of metastatic alveolar rhabdomyosarcoma with MGMT gene promoter methylation by temozolomide‐based combination chemotherapy , 2018, Pediatric blood & cancer.

[12]  C. Rodríguez-Galindo,et al.  Upfront window vincristine/irinotecan treatment of high‐risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee , 2017, Cancer.

[13]  P. Collini,et al.  Vincristine, Irinotecan, and Bevacizumab in Relapsed Wilms Tumor With Diffuse Anaplasia. , 2017, Journal of pediatric hematology/oncology.

[14]  Robert Ford,et al.  RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. , 2016, European journal of cancer.

[15]  H. Brisse,et al.  Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second‐line chemotherapy , 2015, Pediatric blood & cancer.

[16]  K. Matthay,et al.  Phase I/II study of 131I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma , 2015, British Journal of Cancer.

[17]  Yu-Tong Zhang,et al.  Vincristine and Irinotecan in Children with Relapsed Hepatoblastoma: A Single-Institution Experience , 2015, Pediatric hematology and oncology.

[18]  James R. Anderson,et al.  Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. , 2014 .

[19]  C. Balañà,et al.  A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma , 2013, Anti-cancer drugs.

[20]  C. Rodríguez-Galindo,et al.  Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma , 2013, Pediatric blood & cancer.

[21]  L. Wagner,et al.  Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors , 2013, Pediatric blood & cancer.

[22]  R. Sposto,et al.  A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors , 2013, PloS one.

[23]  Michael J. Eckrich,et al.  Vincristine, Irinotecan, and Temozolomide for Treatment of Relapsed Alveolar Rhabdomyosarcoma , 2013, Journal of pediatric hematology/oncology.

[24]  William M. Lee,et al.  Clinical and Histological Features of Idiosyncratic Acute Liver Injury Caused by Temozolomide , 2013, Digestive Diseases and Sciences.

[25]  T. MacDonald,et al.  Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience , 2013, Child's Nervous System.

[26]  R. Tsang,et al.  Chemotherapy-Associated Steatohepatitis with Temozolomide and Dexamethasone , 2012, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[27]  H. Herbst,et al.  Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. , 2012, Neuro-oncology.

[28]  Olivier Poch,et al.  In Vivo Topoisomerase I Inhibition Attenuates the Expression of Hypoxia-Inducible Factor 1α Target Genes and Decreases Tumor Angiogenesis , 2012, Molecular medicine.

[29]  D. Yamashiro,et al.  Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. , 2011, The oncologist.

[30]  L. Wagner.  Camptothecin-Based Regimens for Treatment of Ewing Sarcoma: Past Studies and Future Directions , 2011, Sarcoma.

[31]  J. Maris,et al.  Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  James R. Anderson,et al.  Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Heideman,et al.  Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors , 2010, Pediatric blood & cancer.

[34]  L. Wexler,et al.  Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan‐Kettering experience , 2009, Pediatric blood & cancer.

[35]  S. Groshen,et al.  Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M Beth McCarville,et al.  Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy , 2007, Clinical Cancer Research.

[37]  Darell D. Bigner,et al.  Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[38]  M Beth McCarville,et al.  Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma , 2007, Pediatric blood & cancer.

[39]  P. Houghton,et al.  Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  N. Cheung,et al.  Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  R. Christofferson,et al.  The Anti-VEGF Antibody Bevacizumab Potently Reduces the Growth Rate of High-Risk Neuroblastoma Xenografts , 2006, Pediatric Research.

[42]  S. Burchill,et al.  Vascular Endothelial Growth Factor: A Therapeutic Target for Tumors of the Ewing's Sarcoma Family , 2005, Clinical Cancer Research.

[43]  M. Iskander,et al.  Microtubulin binding sites as target for developing anticancer agents. , 2004, Mini reviews in medicinal chemistry.

[44]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[45]  M. Gruber,et al.  Temozolomide in Combination With Irinotecan for Treatment of Recurrent Malignant Glioma , 2004, American journal of clinical oncology.

[46]  A. Tolcher,et al.  Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules , 2003, British Journal of Cancer.

[47]  P. Houghton,et al.  Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors , 2004, Cancer Chemotherapy and Pharmacology.

[48]  Y. Pommier,et al.  Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. , 2001, Cancer research.

[49]  E S Newlands,et al.  Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. , 1997, Cancer treatment reviews.